Hormonal
Statins are effective for primary and secondary prevention of cardiovascular disease in patients with diabetes, providing significant risk reduction even in patients with low baseline LDL cholesterol.
If you have diabetes, you should likely be on a statin, even if your cholesterol numbers look okay. Statins significantly reduce your risk of heart attack and stroke, and this benefit exists regardless of your baseline LDL. The small risk of developing diabetes from statins is far outweighed by the protection they offer your heart. Discuss high-intensity statins with your doctor if you are over 40 or have other risk factors.
There is a wealth of clinical trial evidence that lowering serum cholesterol with statins decreases the risk of CHD... It would appear from such trials that the relative risk reduction achieved with statin treatment is similar in patients with diabetes to that in other people.
Why this rating
Backed by multiple large RCTs (CARDS, HPS, 4S, etc.) and meta-analyses.
Source
Diabetes Dyslipidemia
Jonathan Schofield et al. · Diabetes Therapy · 2016
DOI 10.1007/s13300-016-0167-x
More from this paper
- Intensive glycemic control fails to significantly improve cardiovascular outcomes in patients with diabetes, whereas cholesterol-lowering therapy significantly reduces cardiovascular events regardless of baseline lipid profiles.Strong
- In patients with diabetes, LDL cholesterol concentration is a poor indicator of cardiovascular risk because it masks an increased number of atherogenic lipoprotein particles (high apoB) and the presence of small, dense LDL particles.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →